|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
9,000,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Baudax Bio is a pharmaceutical company primarily focused on commercializing and developing products for hospital and related acute care settings. Co. has launched its commercial product, ANJESO in the U.S. ANJESO is an intravenous analgesic agent. ANJESO is a cyclooxygenase-2 preferential, non-steroidal anti-inflammatory, or NSAID for the management of moderate to severe pain, which can be administered alone or in combination with other non-NSAID analgesics. Co.'s pipeline also includes other earlier stage product candidates including intermediate and short-acting neuromuscular blocking agents, and accompanying reversal agents that Co. is developing for use in hospital or related settings.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
1,200 |
| Total Buy Value |
$0 |
$0 |
$0 |
$3,057 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Weisman Wayne |
Director |
– • – |
2019-12-05 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
30,582 |
|
- |
|
| Ashton William |
Director |
– • – |
2019-12-05 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
27,782 |
|
- |
|
| Henwood Geraldine |
President and CEO |
• • – |
2019-12-05 |
4 |
A |
$0.00 |
$0 |
D/D |
323,958 |
353,868 |
|
- |
|
| Recro Pharma, Inc. |
10% Owner |
– – • |
2019-11-21 |
4 |
D |
$0.00 |
$0 |
D/D |
(9,211,245) |
0 |
|
- |
|
| Recro Pharma, Inc. |
10% Owner |
– – • |
2019-11-21 |
4 |
A |
$0.00 |
$0 |
D/D |
9,211,145 |
9,211,245 |
|
- |
|
| Recro Pharma, Inc. |
10% Owner |
– – • |
2019-11-12 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
100 |
|
- |
|
56 Records found
|
|
Page 3 of 3 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
